not used title
not used title
We’ve seen significant progress in recent years in the treatment of cancer, and that progress is expected to continue. A new report released this month found that there are more than 240 new immuno-oncology treatments in development – treatments designed to enable the patient’s own immune system to fight cancer.
The report, “Medicines In Development: Immuno-Oncology,” takes a closer look at a handful of classes of immune-oncology medicines, including adoptive cell therapies (including CAR-T therapy), bi-specific antibodies, cytokines, immune checkpoint modulators, oncolytic virus therapies and vaccines. These new treatments will serve previously unmet medical needs and provide new hope for the future.
While Americans of all ages are at risk of being diagnosed with cancer, it is more prevalent in older Americans. In fact, patients age 50 and older make up 87 percent of cancer diagnoses in the United States, making finding new, innovative cancer treatments even more critical for seniors.
For seniors diagnosed with cancer, Medicare Part B provides the coverage they need for their physician-administered cancer medicines. Short-sighted changes to Part B, such as those proposed by the Medicare Payment Advisory Commission (MedPAC), could restrict patients’ ability to access innovative cancer treatments and deter investment in the next generation of cancer medicines. MedPAC’s proposed changes would impede the competitive market through government price setting, including a restrictive binding arbitration process to set prices for new drugs.
As America’s biopharmaceutical companies continue to push forward in the research and development of new cancer medicines, it is important to protect beneficiaries’ access to Part B medicines and preserve incentives for innovation in complex disease areas, like cancer.
Learn more about Part B at PhRMA.org/PartB and find the report here.
Nicole Longo
Nicole Longo is Deputy Vice President of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Nicole Longo
Author Twitter
Author LinkedIn
What AARP isn’t telling seniors about MFN
August 24, 2026
CMS proposal could discourage patient-centered innovation
August 18, 2026
Nearly 1 in 4 patients initially denied access to IRA medicines
August 6, 2026
Medicare Part D at 20: Building on a strong foundation
July 23, 2026
New study: HPV vaccination helps prevent cervical cancer deaths
July 21, 2026
America's cancer research progress is real and worth protecting
May 28, 2026
Ahead of ASCO: Cancer innovation is promising, but policy choices matter
May 26, 2026
MFN won’t lower costs when insurers call the shots
May 8, 2026
Guest Blog: How MFN price controls could decide my health care
April 30, 2026
States should avoid repeating the IRA’s price‑setting mistakes
April 21, 2026
Insurers routinely block seniors’ access to medicines in Medicare Part D
March 18, 2026
MFN undermines U.S. biopharmaceutical innovation
February 25, 2026
CMS puts patients and innovation at risk with MFN
February 24, 2026
Advancing patient care: A look at new medicines approved in 2025
January 30, 2026
New list of selected drugs highlights growing consequences of government price setting
January 28, 2026
CAREs 2025: Supporting community-based solutions that improve access to medicines
January 22, 2026
New analysis finds 340B hospitals push patients toward costly care to boost profits
January 21, 2026
Price setting policies put cancer gains in jeopardy
January 16, 2026
Guest blog: Making the most of the Medicare Prescription Payment Plan
December 8, 2025
What seniors can expect this open enrollment
October 14, 2025
Part D premiums are going up, while choices are going down
October 8, 2025
Delivering breakthroughs and lower costs for patients
September 8, 2025
Celebrating 60 Years of Medicare
July 30, 2025
Medicare patients face higher drug costs, despite IRA promises
July 22, 2025
Medicare Part D plans initially denied medicines for more than 70% of patients in four chronic disease areas
June 16, 2025
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
February 25, 2025
CMS, don’t fall behind the rest of the medical community on obesity
February 14, 2025
Guest Perspective: Prioritize Innovative Care
February 11, 2025
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
February 3, 2025
A new administration poses new opportunities for patient access
December 17, 2024
Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.
November 13, 2024
The Patient Perspective: Vaccines
October 23, 2024
Is CMS paying attention to the growing access barriers for Medicare patients under the IRA?
October 18, 2024
The importance of partnership: A conversation with Takeda
October 10, 2024
Did the administration consider the importance of blood cancer medicines to patients in price setting process?
October 8, 2024
New Report: Tackling chronic conditions with preventive treatment
September 30, 2024
Did the administration consider the importance of blood clot medicines to patients in the price setting process?
September 25, 2024
The Inflation Reduction Act could increase costs and reduce access for millions of seniors
September 17, 2024
Are the IRA’s Part B inflation rebates lowering costs for Medicare patients? No.
September 16, 2024
Did the administration consider the value of innovative diabetes medicines in price setting process?
August 28, 2024
New survey: Insurers confirm IRA will reduce patient treatment options
August 20, 2024
The unintended consequences of government price setting in Medicare Part D
August 16, 2024
Don’t put the government between patients and their medicines
August 7, 2024
Biosimilars continue to drive market competition and increase savings for seniors
August 6, 2024
What is the low-income subsidy program and how is it changing?
July 31, 2024
Case study: How seniors could face access disruptions because of the IRA’s price setting provisions
July 22, 2024
New Report: Vaccines continue to drive improved health outcomes
July 16, 2024
The future of oncology R&D lies in policymakers’ hands
July 8, 2024
PhRMA reiterates concerns with IRA price setting program, urges CMS to mitigate harm
July 3, 2024
Showcasing the promise of biopharma at ASCO 2024
June 28, 2024
The IRA could lead to higher out-of-pocket costs for 3.5 million Medicare patients in 2026
June 25, 2024
Mental Health Awareness Month: Supporting loved ones and improving mental health in America
May 28, 2024
Championing cancer equity: Our drive for healthier AANHPI communities
May 1, 2024
IRA is already negatively impacting access to medicines in Part D
April 25, 2024
New study finds insurers and PBMs increasing access restrictions in Medicare Part D
April 16, 2024
New analysis: Flawed assessments of a medicine’s value jeopardize patient access
April 11, 2024
The impact of innovative medicines: A caregiver's perspective
March 26, 2024
PhRMA awards $250,000 to community-based projects to improve equitable cancer outcomes
February 9, 2024
Three things to know about antibody drug conjugates
February 2, 2024
As the administration continues to falsely claim Medicare “negotiation,” keep these points in mind
February 1, 2024
The IRA’s pill penalty threatens the future of oncology R&D
November 16, 2023
New Report: 1,600 cancer treatments and vaccines in clinical development
November 9, 2023
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
November 6, 2023
R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot
October 18, 2023
ICYMI: Government watchdog report finds patients in Medicare Part D paid billions more for medicines than insurers and PBMs
September 28, 2023
IRA threatens seniors’ access to robust treatment options
September 26, 2023
Medicare Prescription Payment Plan will benefit patients if implemented correctly
September 21, 2023
Correcting the record: IRA’s government price setting provisions are unconstitutional
September 8, 2023
IRA changes to Part D risk access to medicines
August 24, 2023
Watch: New video series spotlights advances in biopharmaceutical science
August 24, 2023
With the first list of medicines out, let’s not forget why government price setting is bad policy
August 22, 2023
One year later IRAs unintended consequences are becoming reality
August 16, 2023
AARP’s latest misleading report
August 11, 2023
Between hope and despair: Improving cancer outcomes
July 11, 2023
New report shows high-impact R&D happens after cancer medicines are first approved
July 10, 2023
New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines
June 22, 2023
ASCO 2023: Protecting our progress in the fight against cancer
June 15, 2023
Highlights from ASCO 2023
June 8, 2023
Four things for CMS to keep in mind as they implement changes to Part D
June 7, 2023
Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation
May 11, 2023
Support for continued progress is critical for pediatric drug development
May 8, 2023
CMS guidance on IRA price setting process doubles down on bad policy
April 14, 2023
A guide to MedPAC’s Part B vote today
April 13, 2023
MedPAC proposal threatens access to medicines in Part B
April 6, 2023
CMS coverage policy is detrimental to Alzheimer’s patients
April 4, 2023
How Part B’s ASP system helps control costs for the government and seniors
March 30, 2023
New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans
March 28, 2023
Medicare Part B spending in four points
March 28, 2023
IRA Impacts: Cancer treatment research and development
March 23, 2023
State policymakers can protect American innovation and help Americans live longer, healthier lives
February 9, 2023
Recognizing National Glaucoma Awareness Month
February 1, 2023
New Report More than 160 medicines in development for mental illness
January 26, 2023
ICYMI: Cancer death rate continues to decline due to treatment advances
January 25, 2023
Novel medicines approved in 2022 offer increased treatment options for patients
January 23, 2023
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
December 1, 2022
Medicare Part D open enrollment and what recent changes mean for beneficiaries
November 17, 2022
ICYMI: PhRMA COO Lori Reilly Esq. speaks with Jacob Van Naarden about the future of cancer research
November 8, 2022
Protecting treatment advances for breast cancer
October 31, 2022
Many seniors are paying more for Part D medicines than their insurer
October 18, 2022
Biosimilar uptake is increasing and so are health savings
October 17, 2022
Busting 3 Myths About Copay Coupons
October 5, 2022
New Report: Nearly 800 medicines in development to treat chronic conditions
September 29, 2022
Recognizing National Sickle Cell Awareness Month
September 23, 2022
CMS coverage policies restrict patient access to important treatment options for Alzheimer’s disease
September 1, 2022
Myth vs. Fact: The Senate’s latest price setting proposal
August 5, 2022
The Senate’s latest price setting proposal will undermine U.S. economic growth
August 3, 2022
Celebrating Medicare’s 57th anniversary
August 2, 2022
The Senate’s latest price setting proposal will undermine: Our health care system
July 28, 2022
The Senate’s latest price setting proposal will undermine: Patient access to medicines
July 26, 2022
New research shows competition driven by biosimilars helps control costs in Part B
July 19, 2022
Polling continues to show voters reject so-called Medicare “negotiation” once they learn about consequences for patients
July 12, 2022
CMS coverage decision restricts access to treatments for Alzheimer’s disease
June 22, 2022
Key takeaways from ASCO's annual meeting
June 10, 2022
Potential gene therapies bring hope to patients with sickle cell disease
June 6, 2022
ICYMI: First pediatric patient to receive CAR-T cell therapy celebrates 10 years of being cancer-free
May 25, 2022
Gene therapies can reduce treatment burden and costs for patients with blood disorders
May 18, 2022
Report: More than 500 medicines in development to treat disorders of the blood
May 18, 2022
Annual projections from NHE compared to actual health care spending
May 5, 2022
Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities
April 27, 2022
Part D 101: Three charts show how the program provides comprehensive prescription drug coverage
April 26, 2022
Report: More than 600 medicines in development for diseases affecting women
March 31, 2022
4 things to know about biopharmaceutical efforts to fight cancer
February 24, 2022
Government price setting leaves behind families counting on new medicines
February 23, 2022
Part B 101: Three charts show the program helps control costs for health care system and enrollees
February 18, 2022
PhRMA submits comments urging CMS to withdraw coverage proposal
February 11, 2022
Government price setting won’t stop insurers from shifting costs to patients
February 2, 2022
Research and development continues long after a medicine is initially approved
February 1, 2022
It’s a new year, but sadly Congress is still pursuing flawed price setting policies
January 25, 2022
New data show continued decline in death rates for cancer patients related to treatment advances
January 20, 2022
Post-approval research save lives. Why is Congress trying disincentivize it?
December 17, 2021
New Report: Nearly 800 new medicines in development to treat rare diseases
December 16, 2021
A price control by any other name would still put patients at risk and threaten innovation
December 9, 2021
Making medicines more affordable: Making insurance work like insurance
December 8, 2021
3 things to know about the importance of post-approval research and development
December 6, 2021
Guest post: Congress should not put future innovation at risk
November 29, 2021
What is missing in the current drug pricing plan
November 23, 2021
ICYMI: PhRMA CEO speaks at STAT Summit about government price setting
November 19, 2021
Three things to know about so-called Medicare negotiation polling
November 18, 2021
In the current health care debate, Congress has lost sight of what matters to U.S. voters
November 15, 2021
Making medicines more affordable: Modernizing Medicare
November 11, 2021
What they are saying: Government price setting for medicines is not the answer
November 4, 2021
Guest post: Continued research and development is critical for ALS patients and families
October 25, 2021
CMS finds medication adherence saved Medicare up to 46.6B in avoided health care costs between 2013 and 2018
October 19, 2021
ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development
October 18, 2021
New poll shows Americans reject Medicare negotiation once they learn more about the policy
October 15, 2021
New report shows more than 260 medicines in development to fight neurodegenerative diseases
October 12, 2021
What is Kaiser Family Foundation up to?
October 12, 2021
Industry leaders discuss the impact of the drug pricing debate
September 23, 2021
Five reasons tying VA prices to Medicare Part D misses the mark
September 22, 2021
America’s biopharmaceutical companies to Congress: Government “negotiation” is the wrong approach
September 15, 2021
Recognizing National Immunization Awareness Month
August 31, 2021
Recent polling misrepresents public support for Medicare “negotiation”
August 31, 2021
What they’re saying: Patient advocates want to protect Medicare from government interference
August 24, 2021
Myth vs. fact: Polling and Medicare “negotiation”
August 12, 2021
ICYMI: Event spotlights how we can make Medicare work better for patients
August 4, 2021
Celebrating Medicare’s 56th anniversary
July 30, 2021
Government “negotiation” could have devastating consequences for Medicare enrollees
July 23, 2021
Protecting Medicare from government interference
July 21, 2021
Data shows voters strongly support protecting access to their medicines
July 15, 2021
Medicare “negotiation” proposals threaten Americans’ access to medicines
June 30, 2021
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
June 22, 2021
The ABCs (and Ds) of Medicare
May 13, 2021
New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections
April 29, 2021
ICYMI: Bipartisan lawmakers urge new administration to oppose changes to six protected classes policy
March 11, 2021
Key excerpts: PhRMA submits comments to keep the six protected classes protected
February 19, 2021
Action needed to preserve the six protected classes
February 3, 2021
ICYMI: Cancer death rate continues decline due to advances in treatment
January 19, 2021
End of year Part D reading List
December 18, 2020
Report: More than 1,300 medicines and vaccines in development to help fight cancer
December 15, 2020
New analysis finds stark difference in coverage of breast cancer medicines for seniors in the United States and England
December 10, 2020
No matter how you look at it, the Most Favored Nation rule is bad policy
December 1, 2020
Final rebate rule represents right way to change Medicare
December 1, 2020
Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015
October 21, 2020
Open Enrollment: How to find a Medicare plan that meets your needs
October 14, 2020
Three reasons why repealing the Part D non-interference clause is a bad idea
October 1, 2020
Supporting access to vaccines for Part D beneficiaries
August 12, 2020
Medicare’s 55th anniversary: Celebrating the success of Part D
July 30, 2020
New report explores setbacks that bring future cancer success stories
July 16, 2020
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
June 24, 2020
PhRMA submits comments to CMS on policy changes for in-home care under Part B during COVID-19
May 6, 2020
New report shows nearly 260 vaccines in development, including dozens for COVID-19
April 23, 2020
Nearly 400 cell and gene therapies in development to target a broad range of diseases
March 10, 2020
Three reasons the Administration should abandon its International Pricing Index proposal
January 31, 2020
Cancer medicines cost twice as much at hospitals, study finds
January 21, 2020
Event tomorrow: Maintaining America’s leadership in access and innovation
October 16, 2019
Pelosi’s radical plan would leave Alzheimer’s patients behind
October 16, 2019
Nearly 140 medicines in development to treat mental illness
October 10, 2019
What they are saying: Broad opposition to Pelosi’s radical drug pricing plan
October 10, 2019
New analysis: Government intervention in Part B threatens patient access to medicines
August 19, 2019
Setting the record straight on international reference pricing
July 16, 2019
No matter how you structure it, government arbitration is wrong for Medicare drug coverage
June 27, 2019
What you should know: Government arbitration is the wrong way to change Medicare
June 10, 2019
By the numbers: A look at the Part B International Pricing Index Model
June 6, 2019
How the rebate rule would help reduce patients’ out-of-pocket costs
June 3, 2019
Ask About Adherence: Improving adherence among osteoporosis patients could save up to $6.52 billion
May 29, 2019
Ask About Adherence: OIG proposed rule to reform the rebate system could improve adherence
May 15, 2019